Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.

Korenblik, R; Olij, B; Aldrighetti, L A; Hilal, M Abu; Ahle, M; Arslan, B; van Baardewijk, L J; Baclija, I; Bent, C; Claude, Bertrand; Björnsson, B; de Boer, M T; de Boer, S W; Bokkers, R P H; Rinkes, I H M Borel; Breitenstein, S; Bruijnen, R C G; Bruners, P; Büchler, M W; Camacho, J C

doi:10.1007/s00270-022-03176-1

Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.

Korenblik, R

;

Olij, B

;

Aldrighetti, L A

;

Hilal, M Abu

;

van Dam, R M

;et.al.

(2022) Cardiovascular and Interventional Radiology — Vol. 45, n° 9, p. 1391-1398 (2022)

Files

KorenblikRCardiovascInterventRadiol2022.pdf

Open Access
Adobe PDF
70.44 KB

Download

Details

Authors

Korenblik, R
Author
Olij, B
Author
Aldrighetti, L A
Author
Hilal, M Abu
Author
Claude, BertrandUCLouvain
Author
De Wispelaere, Jean-FrançoisUCLouvain
Author
Dili, AlexandraUCLouvain
Author
van Dam, R M
Author

Abstract

(en) STUDY PURPOSE: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. METHODS: The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. RESULTS: Not applicable. CONCLUSION: DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. TRIAL REGISTRATION: Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).

Affiliations

Citations

APA
Chicago
FWB

Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. A., Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Claude, B., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. B., Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., et al. (2022). Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. Cardiovascular and Interventional Radiology, 45(9), 1391-1398. https://doi.org/10.1007/s00270-022-03176-1 (Original work published 2022)